We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04590781
Title Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Xencor, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
USC/Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756 United States Details
Memorial Sloan Kettering New York New York 10065 United States Details
OU Health, Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
Swedish Cancer Institute Seattle Washington 98109 United States Details
University of Washington Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field